[
  {
    "id": 1,
    "question": "最早用人痘接种预防天花的国家是",
    "options": ["A.中国", "B.美国", "C.英国", "D.俄罗斯", "E.法国"],
    "answer": "A"
  },
  {
    "id": 2,
    "question": "机体免疫稳定功能低下,不导致",
    "options": ["A.免疫缺陷病", "B.免疫增殖病", "C.自身免疫病", "D.恶性肿瘤", "E.超敏反应"],
    "answer": "B"
  },
  {
    "id": 3,
    "question": "免疫自稳功能是指",
    "options": ["A.抑制病原微生物在体内繁殖和扩散", "B.防止自身免疫病的发生", "C.清除体内病原微生物,防止感染", "D.清除体内突变细胞,防止肿瘤发生", "E.防止病毒的持续感染"],
    "answer": "B"
  },
  {
    "id": 4,
    "question": "人体内最大的免疫器官是",
    "options": ["A.胸腺", "B.骨髓", "C.脾", "D.淋巴结", "E.法氏囊"],
    "answer": "C"
  },
  {
    "id": 5,
    "question": "关于免疫应答反应特征的叙述,错误的是",
    "options": ["A.识别自己", "B.识别异己", "C.特异性", "D.记忆性", "E.遗传性"],
    "answer": "E"
  },
  {
    "id": 6,
    "question": "关于特异性免疫效应功能的叙述,错误的是",
    "options": ["A.浆细胞分泌特异性抗体,执行体液免疫功能", "B.辅助性T细胞(Th细胞)分泌细胞因子等效应因子,执行细胞免疫功能", "C.细胞毒性T细胞(CTL细胞)杀伤靶细胞", "D.产生记忆细胞", "E.中性粒细胞吞噬与杀灭细菌"],
    "answer": "E"
  },
  {
    "id": 7,
    "question": "抗原自凝现象出现于",
    "options": ["A.反应pH达到或接近颗粒抗原的等电点", "B.反应pH达到或接近抗原的等电点", "C.反应pH高于颗粒抗原的等电点", "D.反应pH低于颗粒抗原的等电点", "E.反应pH高于抗原的等电点"],
    "answer": "A"
  },
  {
    "id": 8,
    "question": "用已知抗原或抗体来检测相对应的抗体或抗原,是由于抗原抗体反应具有",
    "options": ["A.特异性", "B.比例性", "C.可逆性", "D.亲和性", "E.带现象"],
    "answer": "A"
  },
  {
    "id": 9,
    "question": "外斐反应的原理是利用了",
    "options": ["A.过量抗原", "B.共同抗原", "C.过量抗体", "D.亲和性", "E.可逆反应"],
    "answer": "B"
  },
  {
    "id": 10,
    "question": "关于免疫血清制备的叙述,正确的是",
    "options": ["A.早期获得的抗血清亲和力低,特异性好", "B.早期获得的抗血清亲和力高,特异性好", "C.早期获得的抗血清亲和力低,特异性低", "D.后期获得的抗血清亲和力低,特异性好", "E.后期获得的抗血清亲和力高,特异性好"],
    "answer": "A"
  },
  {
    "id": 11,
    "question": "在抗原抗体反应中,通常使用的抗原抗体稀释液是",
    "options": ["A.0.70% NaCl溶液", "B.0.60% NaCl溶液", "C.0.75% NaCl溶液", "D.0.85% NaCl溶液", "E.0.95% NaCl溶液"],
    "answer": "D"
  },
  {
    "id": 12,
    "question": "静电引力大小是",
    "options": ["A.和两个电荷的距离成正比", "B.和两个电荷的距离的平方成比例关系", "C.和两个电荷的距离成反比", "D.和两个电荷的距离的平方成反比", "E.和两个电荷的距离平方不成比例关系"],
    "answer": "D"
  },
  {
    "id": 13,
    "question": "抗原抗体反应比例不合适出现的沉淀物减少的现象称为",
    "options": ["A.前带", "B.后带", "C.带现象", "D.等价带", "E.等电点"],
    "answer": "C"
  },
  {
    "id": 14,
    "question": "平衡常数(K)是表示抗原抗体反应的",
    "options": ["A.特异性", "B.亲和性", "C.比例性", "D.可逆性", "E.非特异性"],
    "answer": "D"
  },
  {
    "id": 15,
    "question": "关于抗原抗体反应的特点的叙述,正确的是",
    "options": ["A.抗原抗体反应有交叉反应,故抗原抗体反应特异性不强", "B.抗原抗体反应必须在抗体量略大于抗原量时,形成的复合物最大", "C.抗原抗体反应形成的复合物又可解离为游离的抗原与抗体", "D.抗体与抗原结合牢固,不易被解离", "E.抗原抗体反应分为两个阶段,两个阶段之间有明显的界限"],
    "answer": "C"
  },
  {
    "id": 16,
    "question": "抗原抗体反应的影响因素中关于反应物自身的因素的叙述,错误的是",
    "options": ["A.抗原的性质", "B.抗体的亲和力", "C.电解质", "D.抗体的浓度", "E.抗体的特异性"],
    "answer": "C"
  },
  {
    "id": 17,
    "question": "从组织和细胞匀浆中粗提某种蛋白抗原,最常用又简便的分离方法是",
    "options": ["A.盐析法", "B.凝胶过滤法", "C.离子交换层析法", "D.免疫亲和层析法", "E.免疫电泳法"],
    "answer": "A"
  },
  {
    "id": 18,
    "question": "根据抗原分子所带电荷不同进行分离纯化的方法称为",
    "options": ["A.盐析法", "B.凝胶过滤法", "C.离子交换层析法", "D.免疫亲和层析法", "E.免疫电泳法"],
    "answer": "C"
  },
  {
    "id": 19,
    "question": "免疫小鼠采血通常采用",
    "options": ["A.心脏采血或断尾法", "B.颈动脉放血或断尾法", "C.颈静脉或摘除眼球采血", "D.摘除眼球或断尾法", "E.耳静脉采血或摘除眼球"],
    "answer": "D"
  },
  {
    "id": 20,
    "question": "弗式完全佐剂的组成是",
    "options": ["A.液体石蜡+羊毛脂", "B.羊毛脂+氢氧化铝", "C.液体石蜡+卡介苗+氢氧化铝", "D.卡介苗+氢氧化铝+羊毛脂", "E.卡介苗+液体石蜡+羊毛脂"],
    "answer": "E"
  },
  {
    "id": 21,
    "question": "需制备10mL抗血清,可选择的免疫动物是",
    "options": ["A.家兔", "B.小白鼠", "C.马", "D.绵羊", "E.猴"],
    "answer": "A"
  },
  {
    "id": 22,
    "question": "在HAT选择培养基中可长期存活者的是",
    "options": ["A.细胞多聚体", "B.融合的脾细胞与瘤细胞", "C.融合的瘤细胞与瘤细胞", "D.未融合的瘤细胞", "E.未融合的脾细胞"],
    "answer": "B"
  },
  {
    "id": 23,
    "question": "关于凝集试验的叙述,错误的是",
    "options": ["A.GAT", "B.P Coombs 试验", "C.PAMP", "D.TRUST", "E.LAT"],
    "answer": "C"
  },
  {
    "id": 24,
    "question": "关于间接血凝试验的叙述,错误的是",
    "options": ["A.红细胞作为载体", "B.不能检测抗原", "C.可检测抗体", "D.可判断阳性反应的强弱", "E.应用广泛"],
    "answer": "B"
  },
  {
    "id": 25,
    "question": "关于应用间接凝集反应检测对象的叙述,错误的是",
    "options": ["A.抗体", "B.AFP 抗原", "C.伤寒沙门菌菌体抗原", "D.类风湿因子", "E.HCG 抗原"],
    "answer": "C"
  },
  {
    "id": 26,
    "question": "关于间接 Coombs 试验的叙述,错误的是",
    "options": ["A.检测红细胞上的不完全抗体", "B.出现凝集为阳性", "C.抗原致敏红细胞", "D.用于检测母体 Rh抗体", "E.可检测因红细胞不相容性输血而产生的溶血"],
    "answer": "A"
  },
  {
    "id": 27,
    "question": "协同凝集试验所用的载体是",
    "options": ["A.新鲜红细胞", "B.洗涤红细胞", "C.醛化红细胞", "D.聚苯乙烯颗粒", "E.金黄色葡萄球菌"],
    "answer": "E"
  },
  {
    "id": 28,
    "question": "单向免疫扩散试验,ManCini 曲线适用于",
    "options": ["A.小分子抗原,长时间扩散(48h)", "B.小分子抗原,短时间扩散(24h)", "C.大分子抗原,长时间扩散(48h)", "D.大分子抗原,短时间扩散(24h)", "E.不论分子大小"],
    "answer": "C"
  },
  {
    "id": 29,
    "question": "双向琼脂扩散试验中,若抗原含量较大,反应沉淀线则",
    "options": ["A.靠近抗原孔", "B.靠近抗体孔", "C.在两孔之间", "D.沉淀线弯向抗原孔", "E.呈多条沉淀线"],
    "answer": "B"
  },
  {
    "id": 30,
    "question": "分析血清中数种蛋白质抗原成分时常可采用",
    "options": ["A.免疫电泳法", "B.双向扩散试验", "C.单向扩散试验", "D.火箭免疫电泳", "E.对流免疫电泳"],
    "answer": "A"
  },
  {
    "id": 31,
    "question": "免疫电泳主要观察的是",
    "options": ["A.沉淀环的直径", "B.沉淀弧的长短", "C.沉淀峰的高低", "D.沉淀线的数目、形状和位置", "E.沉淀弧的方向"],
    "answer": "D"
  },
  {
    "id": 32,
    "question": "关于透射免疫比浊法的叙述,正确的是",
    "options": ["A.测定光线通过反应混合液时,被其中免疫复合物反射的光的强度", "B.测定光线通过反应混合液时,被其中免疫复合物折射的光的强度", "C.测定光线通过反应混合液时,被其中免疫复合物散射的光的强度", "D.测定光线通过反应混合液时,透过的光的强度", "E.测定光线通过反应混合液时,透射光的色差"],
    "answer": "D"
  },
  {
    "id": 33,
    "question": "可引起深部感染最常见的真菌是",
    "options": ["A.隐球菌", "B.曲霉", "C.念珠菌", "D.肺孢子菌", "E.地霉"],
    "answer": "C"
  },
  {
    "id": 34,
    "question": "属于DNA 病毒的是",
    "options": ["A.HAV", "B.HBV", "C.HCV", "D.HDV", "E.HEV"],
    "answer": "B"
  },
  {
    "id": 35,
    "question": "HSV 最常见的先天性感染途径是",
    "options": ["A.宫内感染", "B.产道感染", "C.产后接触感染", "D.呼吸道感染", "E.消化道感染"],
    "answer": "B"
  },
  {
    "id": 36,
    "question": "关于禽流感病毒属于免疫反应检测的叙述,错误的是",
    "options": ["A.血凝抑制试验", "B.免疫层析试验", "C.免疫扩散试验", "D.红细胞凝集试验", "E.酶联免疫吸附试验"],
    "answer": "D"
  },
  {
    "id": 37,
    "question": "关于临床常用的乙型肝炎病毒免疫学诊断项目的叙述,错误的是",
    "options": ["A.HBsAg", "B.HBeAg", "C.HBcAg", "D.HBeAb", "E.HBcAb"],
    "answer": "C"
  },
  {
    "id": 38,
    "question": "关于乙型肝炎病毒检测的叙述,正确的是",
    "options": ["A.乙肝患者血清中最早出现的病毒标志物是HBeAg", "B.HBsAg 和抗 HBs不可能同时出现", "C.HBcAb是乙型肝炎病毒存在的直接证据", "D.HBeAg 是乙型肝炎传染性的标志,与HBV复制成正比", "E.HBcAb IgG 属于保护性抗体"],
    "answer": "D"
  },
  {
    "id": 39,
    "question": "经胃肠传播,水源污染是其暴发流行主要原因的肝炎病毒是",
    "options": ["A.HAV", "B.HBV", "C.HCV", "D.HDV", "E.HEV"],
    "answer": "E"
  },
  {
    "id": 40,
    "question": "ASO 检测结果可能出现假阴性的是",
    "options": ["A.急性咽炎患者使用大量激素", "B.风湿性心肌炎", "C.风湿性关节炎", "D.急性肾小球肾炎", "E.上呼吸道感染"],
    "answer": "A"
  },
  {
    "id": 41,
    "question": "关于妊娠前致畸病原体检查的叙述,错误的是",
    "options": ["A.PIV", "B.TOX", "C.CL", "D.RV", "E.HSV"],
    "answer": "A"
  },
  {
    "id": 42,
    "question": "感染性疾病出现最早、消失快,可作为感染早期间接诊断指标的免疫球蛋白是",
    "options": ["A.IgA", "B.IgD", "C.IgE", "D.IgG", "E.IgM"],
    "answer": "E"
  },
  {
    "id": 43,
    "question": "伤寒沙门菌抗-O血清凝集效价有诊断意义的是",
    "options": ["A.≥1:10", "B.≥1:20", "C.≥1:40", "D.≥1:60", "E.≥1:80"],
    "answer": "E"
  },
  {
    "id": 44,
    "question": "关于轮状病毒感染的叙述,正确的是",
    "options": ["A.轮状病毒主要经血液传播", "B.轮状病毒主要引起成人腹泻,婴幼儿通常为隐性感染", "C.ELISA 检测患者血清中轮状病毒抗原,如结果阳性则可诊断为轮状病毒感染", "D.轮状病毒血清IgM抗体检测通常用于早期诊断", "E.轮状病毒IgG抗体的检测不能用于流行病学调查"],
    "answer": "D"
  },
  {
    "id": 45,
    "question": "HIV 感染诊断的金标准是",
    "options": ["A.病毒 RNA", "B.P24 抗原", "C.CD4 T细胞检测", "D.HIV抗体检测", "E.CD8 T细胞检测"],
    "answer": "D"
  },
  {
    "id": 46,
    "question": "华支睾吸虫感染的确诊方法是",
    "options": ["A.酶联免疫吸附试验", "B.免疫层析试验", "C.粪便镜检", "D.间接血凝试验", "E.免疫渗透试验"],
    "answer": "C"
  },
  {
    "id": 47,
    "question": "关于 TP 感染非特异性检验项目的叙述,错误的是",
    "options": ["A.RPR", "B.CLIA", "C.VDRL", "D.TRUST", "E.USR"],
    "answer": "C"
  },
  {
    "id": 48,
    "question": "关于I型超敏反应特点的叙述,错误的是",
    "options": ["A.发生快,消退也快", "B.需要 IgE 和补体的参与", "C.多无严重的组织细胞损伤", "D.与遗传有关", "E.有明显的个体差异"],
    "answer": "B"
  },
  {
    "id": 49,
    "question": "介导发生 I 型超敏反应的抗体是",
    "options": ["A.IgG", "B.IgE", "C.IgA", "D.IgD", "E.IgM"],
    "answer": "B"
  },
  {
    "id": 50,
    "question": "关于 I 型超敏反应发生的叙述,错误的是",
    "options": ["A.变应原", "B.个体差异性", "C.FcyR I", "D.嗜碱性粒细胞", "E.肥大细胞"],
    "answer": "C"
  },
  {
    "id": 51,
    "question": "易诱导B细胞产生特异性IgE抗体的细胞因子是",
    "options": ["A.IL-1", "B.IL-2", "C.IL-3", "D.IL-4", "E.IL-12"],
    "answer": "D"
  },
  {
    "id": 52,
    "question": "属于I型超敏反应的是",
    "options": ["A.过敏性休克样反应", "B.新生儿溶血病", "C.系统性红斑狼疮", "D.过敏性休克", "E.传染性变态反应"],
    "answer": "D"
  },
  {
    "id": 53,
    "question": "脱敏疗法适用于",
    "options": ["A.青霉素过敏者", "B.抗毒素过敏,而又必须使用者", "C.食物过敏者", "D.可以避免接触变应原者", "E.药物过敏者"],
    "answer": "B"
  },
  {
    "id": 54,
    "question": "参与 IV 型超敏反应的是",
    "options": ["A.肥大细胞、嗜碱性粒细胞及致敏淋巴细胞", "B.抗原、迟发型超敏反应T细胞(TDTH)和巨噬细胞", "C.抗原、抗体、补体及巨噬细胞", "D.抗体、抗原及抗原抗体复合物", "E.中性粒细胞"],
    "answer": "C"
  },
  {
    "id": 55,
    "question": "与II型超敏反应无关的是",
    "options": ["A.NK细胞", "B.吞噬细胞", "C.补体", "D.肥大细胞", "E.中性粒细胞"],
    "answer": "D"
  },
  {
    "id": 56,
    "question": "青霉素引发的溶血性贫血的机制是",
    "options": ["A.青霉素吸附至红细胞,与相应抗体结合后激活补体", "B.红细胞膜上出现补体受体", "C.青霉素吸附至红细胞后直接活化补体", "D.吸附到红细胞上的补体结合青霉素", "E.抗体的直接溶血作用"],
    "answer": "A"
  },
  {
    "id": 57,
    "question": "Rh血型不符引起的新生儿溶血病多发生于",
    "options": ["A.Rh(-) 母亲所生 Rh(-) 胎儿", "B.Rh(+) 母亲所生 Rh(+) 胎儿", "C.Rh(-) 母亲所生Rh(+)胎儿", "D.Rh(+) 母亲所生 Rh(-) 胎儿", "E.Rh(+) 母亲所生0型胎儿"],
    "answer": "C"
  },
  {
    "id": 58,
    "question": "ABO血型不符输血后引起的溶血属于",
    "options": ["A.I型超敏反应", "B.II型超敏反应", "C.III型超敏反应", "D.IⅣ型超敏反应", "E.不属于超敏反应"],
    "answer": "B"
  },
  {
    "id": 59,
    "question": "属于Ⅱ型超敏反应的疾病是",
    "options": ["A.Arthus 反应", "B.新生儿溶血病", "C.花粉症", "D.接触性皮炎", "E.血清病"],
    "answer": "B"
  },
  {
    "id": 60,
    "question": "引起Ⅲ型超敏反应组织损伤的主要细胞是",
    "options": ["A.巨噬细胞", "B.红细胞", "C.淋巴细胞", "D.中性粒细胞", "E.NK细胞"],
    "answer": "D"
  },
  {
    "id": 61,
    "question": "Ⅲ型超敏反应的重要病理学特征为",
    "options": ["A.组织充血、水肿坏死和巨噬细胞浸润", "B.组织充血、水肿坏死和中性粒细胞浸润", "C.组织充血、水肿坏死和单核细胞浸润", "D.组织充血、水肿坏死和嗜碱性粒细胞浸润", "E.组织充血、水肿坏死和淋巴细胞浸润"],
    "answer": "B"
  },
  {
    "id": 62,
    "question": "属于Ⅲ型超敏反应的是",
    "options": ["A.溶血性贫血", "B.接触性皮炎", "C.荨麻疹", "D.血清病", "E.异种皮肤排斥反应"],
    "answer": "D"
  },
  {
    "id": 63,
    "question": "IV 型超敏反应的重要病理学特征为",
    "options": ["A.淋巴细胞和单核-巨噬细胞浸润", "B.嗜酸性粒细胞浸润", "C.中性粒细胞浸润", "D.淋巴细胞浸润", "E.分叶中性粒细胞浸润"],
    "answer": "A"
  },
  {
    "id": 64,
    "question": "125 I 常用于放射免疫标记示踪的优点是",
    "options": ["A.衰变时释放的射线,容易探测", "B.化学性质活泼,易于制备标志物", "C.半衰期只有8天,使用安全", "D.核素丰度低,对蛋白质、多肽抗原活性影响小", "E.可以标记甾体化合物"],
    "answer": "B"
  },
  {
    "id": 65,
    "question": "最适合于时间分辨荧光免疫测定的荧光物质是",
    "options": ["A.异硫氰酸荧光素(FITC)", "B.四乙基罗丹明", "C.四甲基异硫氰酸罗丹明", "D.镧系稀十元素(Eu3+)", "E.藻红蛋白"],
    "answer": "D"
  },
  {
    "id": 66,
    "question": "现国内 ELISA 中应用最广泛的底物是",
    "options": ["A.TMB", "B.ABTS", "C.OPD", "D.5-ASA", "E.p-NPP"],
    "answer": "A"
  },
  {
    "id": 67,
    "question": "直接化学发光剂的是",
    "options": ["A.FITC", "B.鲁米诺", "C.吖啶酯", "D.4-MUP", "E.AMPPD"],
    "answer": "C"
  },
  {
    "id": 68,
    "question": "最早用于体液(血液)超微量物质分析的技术是",
    "options": ["A.免疫放射分析", "B.放射免疫分析", "C.酶联免疫吸附试验", "D.胶体金免疫分析", "E.化学发光免疫分析"],
    "answer": "B"
  },
  {
    "id": 69,
    "question": "适合测定小分子抗原的放射免疫技术为",
    "options": ["A.放射受体分析", "B.放射配体分析", "C.放射免疫分析", "D.免疫放射分析", "E.放射自显影"],
    "answer": "C"
  },
  {
    "id": 70,
    "question": "应用放射免疫分析测定血清中甲状腺素水平,需将I标记在",
    "options": ["A.已知甲状腺素", "B.待测甲状腺素", "C.抗甲状腺素抗体", "D.第二抗体", "E.抗抗体"],
    "answer": "A"
  },
  {
    "id": 71,
    "question": "放射免疫分析中兼顾特异性和简便快速的分离方法是",
    "options": ["A.PEG沉淀", "B.双抗体沉淀", "C.双抗体-PEG", "D.滤膜过滤", "E.活性炭吸附"],
    "answer": "C"
  },
  {
    "id": 72,
    "question": "关于IRMA 体外诊断试剂组分的叙述,错误的是",
    "options": ["A.标记抗体", "B.系列标准品抗原", "C.洗涤缓冲液", "D.预包被捕获抗体的塑料试管", "E.PEG 分离溶液"],
    "answer": "E"
  },
  {
    "id": 73,
    "question": "放射免疫试验的缺点是",
    "options": ["A.分析敏感度低", "B.分析特异度低", "C.检测时间长", "D.放射性污染", "E.检测成本高"],
    "answer": "D"
  },
  {
    "id": 74,
    "question": "最早出现的免疫标记试验是",
    "options": ["A.荧光免疫试验", "B.放射免疫试验", "C.酶免疫试验", "D.化学发光免疫试验", "E.胶体金免疫试验"],
    "answer": "A"
  },
  {
    "id": 75,
    "question": "FITC发出的荧光颜色为",
    "options": ["A.蓝色", "B.橘红色", "C.橘黄色", "D.红色", "E.黄绿色"],
    "answer": "E"
  },
  {
    "id": 76,
    "question": "荧光抗体用于固定标本染色时,其F/P值是",
    "options": ["A.1", "B.1.2", "C.1.5", "D.1.8", "E.2.4"],
    "answer": "C"
  },
  {
    "id": 77,
    "question": "关于间接免疫荧光试验的叙述,错误的是",
    "options": ["A.可以检测抗原", "B.可以检测抗体", "C.敏感性较直接法明显提高", "D.特异性较直接法明显提高", "E.用一种标记的抗球蛋白抗体,能检查多种以球蛋白作为抗体的复合物"],
    "answer": "D"
  },
  {
    "id": 78,
    "question": "用 FITC 标记抗体时,FITC与抗体之间的结合靠的是",
    "options": ["A.范德华力", "B.共价键", "C.离子键", "D.氢键", "E.静电引力"],
    "answer": "B"
  },
  {
    "id": 79,
    "question": "间接免疫荧光试验检测组织抗原时,荧光素标记于",
    "options": ["A.抗原", "B.特异性抗体", "C.抗C3抗体", "D.抗免疫球蛋白抗体", "E.抗原-抗体复合物"],
    "answer": "D"
  },
  {
    "id": 80,
    "question": "系元素螯合物的荧光寿命通常为",
    "options": ["A.10-100 ns", "B.100-1000 ns", "C.1-10 µs", "D.10-1000 µs", "E.1-100 ms"],
    "answer": "D"
  },
  {
    "id": 81,
    "question": "关于荧光偏振免疫试验的叙述,错误的",
    "options": ["A.大分子免疫复合物转动慢,偏振荧光强", "B.大分子免疫复合物转动快,偏振荧光强", "C.小分子抗原转动慢,方向性好", "D.小分子抗原转动快,方向性好", "E.偏振荧光强度与转动速度无关"],
    "answer": "A"
  },
  {
    "id": 82,
    "question": "关于荧光物质淬灭因素的叙述,错误的是",
    "options": ["A.苯胺", "B.高温", "C.低温", "D.紫外线照射", "E.碘"],
    "answer": "C"
  },
  {
    "id": 83,
    "question": "关于标记抗体的荧光素的叙述,错误的是",
    "options": ["A.与蛋白质分子形成离子键", "B.与蛋白质结合后不影响蛋白质原有的生化与免疫学性质", "C.标记方法简单,安全无毒", "D.荧光效率高,与蛋白质结合后仍能保持较高的荧光效率", "E.荧光色泽与背景组织色泽对比鲜明"],
    "answer": "A"
  },
  {
    "id": 84,
    "question": "关于 ELISA 检测技术及其应用的叙述,正确的是",
    "options": ["A.不适用于小分子抗原检测", "B.同一厂家的不同批次间的标准曲线基本一致", "C.大分子抗原常采用ELISA 双抗体夹心法检测", "D.温度是决定 ELISA结果成败的最关键因素", "E.是一种均相免疫酶技术"],
    "answer": "C"
  },
  {
    "id": 85,
    "question": "关于ELISA 竞争法的叙述,正确的是",
    "options": ["A.显色程度与待测物浓度成反比", "B.只用于检测抗原", "C.只用于检测抗体", "D.阴性对照管中形成的酶标记复合物最少", "E.适用于大分子抗原检测"],
    "answer": "A"
  },
  {
    "id": 86,
    "question": "ELISPOT 技术的特点有",
    "options": ["A.用于死细胞功能检测", "B.可以分析细胞因子的分泌量", "C.灵敏度低", "D.不能进行高通量筛选", "E.不能从单细胞水平检测"],
    "answer": "B"
  },
  {
    "id": 87,
    "question": "关于酶底物颜色反应组合的叙述,正确的是",
    "options": ["A.AP+p-NPP呈黄色", "B.HRP+OPD呈蓝色", "C.HRP+TMB呈黄色", "D.HRP+p-NPP呈蓝色", "E.HRP+p-NPP呈黄色"],
    "answer": "A"
  },
  {
    "id": 88,
    "question": "ELISA 双抗体夹心法可用于检测",
    "options": ["A.吗啡", "B.抗核抗体", "C.癌胚抗原", "D.胰岛素", "E.类风湿因子"],
    "answer": "C"
  },
  {
    "id": 89,
    "question": "ELISA 方法的酶标二抗具有通用特性的是",
    "options": ["A.一步法", "B.双抗体夹心", "C.捕获法", "D.间接法", "E.竞争法"],
    "answer": "D"
  },
  {
    "id": 90,
    "question": "间接 ELISA 可用于检测",
    "options": ["A.甲胎蛋白", "B.胰岛素", "C.乙型肝炎表面抗原", "D.吗啡", "E.HIV抗体"],
    "answer": "E"
  },
  {
    "id": 91,
    "question": "ELISA 捕获法测定病原体抗体的类型是",
    "options": ["A.IgA", "B.IgE", "C.IgM", "D.IgD", "E.IgG"],
    "answer": "C"
  },
  {
    "id": 92,
    "question": "目前通用标记HRP的方法是",
    "options": ["A.碳化二压胺法", "B.过碘酸钠氧化法", "C.琥珀酸酐法", "D.混合酸酐法", "E.戊二醇交联"],
    "answer": "B"
  },
  {
    "id": 93,
    "question": "ELISA 定性测定中S/CO<1结果判断为阳性反应的是",
    "options": ["A.双抗体夹心法", "B.双抗原夹心法", "C.间接法", "D.捕获法", "E.竞争法"],
    "answer": "E"
  },
  {
    "id": 94,
    "question": "大多数化学发光反应属于",
    "options": ["A.中和反应", "B.置换反应", "C.水解反应", "D.氧化还原反应", "E.分解反应"],
    "answer": "D"
  },
  {
    "id": 95,
    "question": "关于化学发光的叙述,错误的是",
    "options": ["A.化学发光是指伴随化学反应过程所产生的光的发射现象", "B.化学发光是吸收了化学反应中所产生的化学能使分子激发而发射的光", "C.化学发光与荧光形成激发态分子的激发能相同", "D.化学发光必须提供足够的激发能,并由某一步骤单独提供", "E.大多数化学发光反应为氧化还原反应"],
    "answer": "C"
  },
  {
    "id": 96,
    "question": "目前已成为非均相化学发光免疫分析技术的首选分离方法是",
    "options": ["A.固相分离", "B.过滤分离", "C.珠式分离", "D.顺磁性颗粒分离", "E.聚乙二醇法"],
    "answer": "D"
  },
  {
    "id": 97,
    "question": "发射射线的放射性核素有",
    "options": ["A.14C、H、32P", "B.125I、131I、51Cr", "C.60 Co、125I、131I", "D.3H, 32P、 60Co", "E.14C、H Cr"],
    "answer": "A"
  },
  {
    "id": 98,
    "question": "属于电化学发光反应的发光剂是",
    "options": ["A.吖啶酯", "B.三联吡啶钉", "C.AMPPD", "D.三丙胺", "E.鲁米诺"],
    "answer": "B"
  },
  {
    "id": 99,
    "question": "化学发光与荧光的本质区别是",
    "options": ["A.化学发光时间长,荧光的发光时间短", "B.化学发光需要酶催化,而荧光不需要", "C.形成激发态分子的激发能不同", "D.化学发光和荧光的波长不同", "E.荧光物质能直接标记抗原或抗体,而化学发光剂不能"],
    "answer": "C"
  },
  {
    "id": 100,
    "question": "关于吖啶酯发光反应特点的叙述,错误的是",
    "options": ["A.瞬间发光,持续时间短", "B.不需要酶的催化作用", "C.发光在酸性环境下进行", "D.发光反应的本底低", "E.可直接标记抗原或抗体,试剂稳定性好"],
    "answer": "C"
  },
  {
    "id": 101,
    "question": "关于常用的化学发光剂的叙述,正确的是",
    "options": ["A.吖啶酯是一种酶促反应发光剂", "B.在酸性条件下,吖啶酯不需酶的催化可以发光", "C.三丙胺是电化学发光反应的发光剂", "D.鲁米诺及其衍生物是常用的酶促反应发光底物", "E.三联吡啶钉是电化学发光反应的电子供体"],
    "answer": "D"
  },
  {
    "id": 102,
    "question": "属于均相化学发光的是",
    "options": ["A.发光氧通道免疫试验", "B.直接化学发光免疫试验", "C.酶促化学发光免疫试验", "D.电化学发光免疫试验", "E.酶促直接发光免疫试验"],
    "answer": "A"
  },
  {
    "id": 103,
    "question": "关于发光氧通道免疫试验的叙述,错误的是",
    "options": ["A.发光氧通道免疫试验的核心原理是高能单线态氧的产生和传递", "B.发光氧通道免疫试验的免疫反应属于非均相反应模式", "C.能实现对多种生物分子的测定,如DNA、RNA、蛋白质等", "D.反应时间短、灵敏度高、稳定性好", "E.该技术能检测低亲和力生物分子"],
    "answer": "B"
  },
  {
    "id": 104,
    "question": "与强直性脊柱炎相关的HLA抗原是",
    "options": ["A.B27", "B.DR2", "C.DR3", "D.DR4", "E.DR5"],
    "answer": "A"
  },
  {
    "id": 105,
    "question": "血清检测抗GBM抗体阳性的是",
    "options": ["A.肾小球肾炎", "B.肾小管间质性肾炎", "C.间质性肺炎", "D.肺出血肾炎综合征", "E.肾小管损伤性肾炎"],
    "answer": "D"
  },
  {
    "id": 106,
    "question": "属于系统性硬化症特异性抗体的是",
    "options": ["A.抗CCP抗体", "B.抗Sel-70抗体", "C.抗SSA抗体", "D.抗Jo-1抗体", "E.抗Sm抗体"],
    "answer": "B"
  },
  {
    "id": 107,
    "question": "用于自身抗体筛查试验的理想方法,首选",
    "options": ["A.化学发光法", "B.流式荧光法", "C.间接免疫荧光法", "D.ELISA法", "E.免疫印迹法"],
    "answer": "C"
  },
  {
    "id": 108,
    "question": "关于自身抗体检测结果的叙述,错误的是",
    "options": ["A.没有一种自身抗体可单独诊断疾病", "B.ANA阳性表示患者一定存在自身免疫性疾病", "C.某些自身抗体出现于疾病之前,有一定的疾病预测价值", "D.目前仍有很多没有明确靶抗原的荧光模型,其临床意义也不甚明确", "E.一个检测项目用不同实验方法检测,可能会出现差异,需客观看待结果"],
    "answer": "B"
  },
  {
    "id": 109,
    "question": "间接免疫荧光法检测 ANA时,最常用的基质是",
    "options": ["A.鼠肝", "B.鼠肾", "C.鼠胃", "D.HEP-2细胞", "E.人白细胞"],
    "answer": "D"
  },
  {
    "id": 110,
    "question": "以变性IgG的Fc段为靶抗原的自身抗体是",
    "options": ["A.RF", "B.CCP", "C.AKA", "D.ANA", "E.AMA"],
    "answer": "A"
  },
  {
    "id": 111,
    "question": "与原发性胆汁性肝硬化(PBC)最密切相关的自身抗体是",
    "options": ["A.ASMA", "B.LKM-1", "C.LC-1", "D.SLA/LP", "E.AMA M2"],
    "answer": "E"
  },
  {
    "id": 112,
    "question": "属于重症肌无力标志性抗体的是",
    "options": ["A.抗乙酰胆碱受体抗体", "B.抗骨骼肌抗体", "C.抗神经元核抗体1型", "D.抗神经元核抗体2型", "E.抗浦肯野细胞抗体"],
    "answer": "A"
  },
  {
    "id": 113,
    "question": "属于器官特异性自身免疫病的是",
    "options": ["A.类风湿性关节炎", "B.干燥综合征", "C.SLE", "D.系统性硬化症", "E.自身免疫性溶血性贫血"],
    "answer": "E"
  },
  {
    "id": 114,
    "question": "属于单克隆增殖性疾病的是",
    "options": ["A.系统性红斑狼疮", "B.类风湿性关节炎", "C.慢性肝炎", "D.轻链病", "E.慢性感染"],
    "answer": "D"
  },
  {
    "id": 115,
    "question": "原发性巨球蛋白血症患者浆细胞无限制增殖,大量产生的单克隆免疫球蛋白是",
    "options": ["A.IgA", "B.IgG", "C.IgM", "D.IgD", "E.IgE"],
    "answer": "C"
  },
  {
    "id": 116,
    "question": "出现多克隆免疫球蛋白增高的是",
    "options": ["A.多发性骨髓瘤", "B.重链病", "C.轻链病", "D.系统性红斑狼疮", "E.原发性巨球蛋白血症"],
    "answer": "D"
  },
  {
    "id": 117,
    "question": "多发性骨髓瘤患者异常增殖的细胞是",
    "options": ["A.单核细胞", "B.T淋巴细胞", "C.NK细胞", "D.浆细胞", "E.单核-巨噬细胞"],
    "answer": "D"
  },
  {
    "id": 118,
    "question": "免疫增殖性疾病异常增殖的细胞是",
    "options": ["A.白细胞", "B.淋巴细胞", "C.巨噬细胞", "D.单核细胞", "E.中性粒细胞"],
    "answer": "B"
  },
  {
    "id": 119,
    "question": "血清中单一免疫球蛋白异常增高的是",
    "options": ["A.多发性骨髓瘤", "B.慢性肝炎", "C.系统性红斑狼疮", "D.肝硬化", "E.艾滋病"],
    "answer": "A"
  },
  {
    "id": 120,
    "question": "诊断单克隆丙种球蛋白病时,测定免疫球蛋白最常用的定量方法是",
    "options": ["A.荧光免疫电泳", "B.免疫比浊法", "C.免疫固定电泳", "D.放射免疫电泳", "E.酶联免疫吸附试验"],
    "answer": "B"
  },
  {
    "id": 121,
    "question": "鉴定 M蛋白的类型,首选的方法是",
    "options": ["A.血清区带电泳", "B.免疫电泳", "C.免疫固定电泳", "D.免疫球蛋白定量测定", "E.酶联免疫吸附试验"],
    "answer": "C"
  },
  {
    "id": 122,
    "question": "多发性骨髓瘤最常见的类型是",
    "options": ["A.IgG型", "B.IgA 型", "C.IgM 型", "D.IgE型", "E.IgD型"],
    "answer": "A"
  },
  {
    "id": 123,
    "question": "原发性巨球蛋白血症时,异常增高的免疫球蛋白类别是",
    "options": ["A.IgG", "B.IgA", "C.IgM", "D.IgE", "E.IgD"],
    "answer": "C"
  },
  {
    "id": 124,
    "question": "关于免疫浊度法的叙述,错误的是",
    "options": ["A.透射免疫浊度检测必须保证抗体过量", "B.免疫浊度法测定的是抗原-抗体反应的第二个阶段", "C.免疫浊度检测出现测量误差的最主要因素是钩状效应", "D.免疫浊度检测主要用于检测补体、免疫球蛋白", "E.免疫浊度检测是将沉淀反应与自动分析检测系统相结合的技术,灵敏度可达到ng/L水平"],
    "answer": "B"
  },
  {
    "id": 125,
    "question": "免疫浊度检测中,导致钩状效应的主要因素是",
    "options": ["A.抗体分子量过大", "B.抗原分子量过大", "C.抗体浓度过量", "D.抗原浓度过量", "E.反应体系中溶液离子强度过大"],
    "answer": "D"
  },{
    "id": 126,
    "question": "关于自动化免疫检测优点的叙述,错误的是",
    "options": ["A.提高了检测的灵敏度", "B.减轻了人工的劳动强度", "C.降低了检测误差", "D.缩短了分析流程", "E.提高了实验结果的准确性"],
    "answer": "A"
  },
  {
    "id": 127,
    "question": "全自动电化学发光免疫分析技术的发光底物为",
    "options": ["A.三联吡啶钉和三丙胺", "B.辣根过氧化物酶", "C.吖啶酯", "D.B-半乳糖苷酶", "E.碱性磷酸酶"],
    "answer": "A"
  },
  {
    "id": 128,
    "question": "最早用于临床的免疫自动化技术是",
    "options": ["A.速率免疫比浊技术", "B.散射免疫比浊技术", "C.酶联免疫吸附试验", "D.化学发光免疫分析技术", "E.时间分辨荧光免疫分析技术"],
    "answer": "B"
  },
  {
    "id": 129,
    "question": "关于速率散射比浊法的叙述,错误的是",
    "options": ["A.可自动化", "B.抗体过量", "C.理论上不受本底散射信号的干扰", "D.灵敏性高", "E.检测抗原-抗体反应的第二阶段"],
    "answer": "E"
  },
  {
    "id": 130,
    "question": "关于酶免疫自动化分析技术测定的叙述,错误的是",
    "options": ["A.肿瘤标志物的检测", "B.HIV 感染筛查", "C.药物浓度的检测", "D.血清酶类物质的检测", "E.梅毒螺旋体抗体的检测"],
    "answer": "D"
  },
  {
    "id": 131,
    "question": "DiGeorge 综合征患者外周血中数量减少的细胞是",
    "options": ["A.B细胞", "B.T细胞", "C.单核细胞", "D.中性粒细胞", "E.T细胞和B细胞"],
    "answer": "B"
  },
  {
    "id": 132,
    "question": "关于 Bruton综合征的叙述,正确的是",
    "options": ["A.属于先天性T细胞缺陷", "B.为原发性常染色体遗传病", "C.属于先天性补体缺陷", "D.患者接种抗原后不产生抗体应答", "E.细胞免疫功能和体液免疫功能都缺陷"],
    "answer": "D"
  },
  {
    "id": 133,
    "question": "属于吞噬细胞缺陷病的是",
    "options": ["A.慢性肉芽肿", "B.遗传性血管神经性水肿", "C.阵发性血红蛋白尿症", "D.普通变异型免疫缺陷病", "E.SCID"],
    "answer": "A"
  },
  {
    "id": 134,
    "question": "关于获得性免疫缺陷综合征的诊断的叙述,正确的是",
    "options": ["A.潜伏期表现为CD4 T细胞数目下降,CD4+T/CD8 T细胞下降", "B.潜伏期表现为CD4 T/CD8 T细胞升高", "C.AIDS 发病期表现为CD8 T细胞绝对值数目明显下降至200个/µL", "D.典型的AIDS患者易伴发机会性感染和恶性肿瘤,但并不是AIDS 死亡的原因", "E.潜伏期表现为CD8 T细胞数目降低,但CD4+T/CD8+T细胞不变"],
    "answer": "A"
  },
  {
    "id": 135,
    "question": "关于AIDS的致病机制的叙述,错误的是",
    "options": ["A.HIV 主要感染的靶细胞是CD4+T细胞", "B.HIV抗原可通过表位频繁发生变异从而逃逸机体的免疫攻击", "C.DC 细胞在某些条件下可提高病毒感染效率", "D.HIV 不会激活特异性CD8 T细胞", "E.HIV 感染后,可刺激机体产生不同的抗病毒抗体来阻碍病毒感染"],
    "answer": "D"
  },
  {
    "id": 136,
    "question": "检测 B细胞免疫缺陷,最常检测的免疫球蛋白是",
    "options": ["A.IgM、IgG、IgE", "B.IgG、IgA、IgE", "C.IgD、IgA、IgE", "D.IgG、IgM、IgA", "E.IgA、IgD、IgG"],
    "answer": "D"
  },
  {
    "id": 137,
    "question": "关于AIDS 免疫学诊断的常用技术的叙述,错误的是",
    "options": ["A.酶联免疫吸附试验", "B.化学发光免疫分析技术", "C.流式细胞术", "D.趋化功能检测-滤膜渗透法", "E.特异性抗原皮肤试验"],
    "answer": "D"
  },
  {
    "id": 138,
    "question": "检测 B细胞免疫缺陷病,最常用的检测技术是",
    "options": ["A.淋巴细胞转化试验", "B.血清免疫球蛋白水平测定", "C.分泌细胞因子功能测定", "D.特异性抗原皮肤试验", "E.CFSE 标记法测定细胞增殖功能检测"],
    "answer": "B"
  },
  {
    "id": 139,
    "question": "AIDS 最常见的传播途径为",
    "options": ["A.母婴垂直传播、呼吸道传播、食物传播", "B.性传播、呼吸道传播、母婴垂直传播", "C.血液传播、母婴垂直传播、性传播", "D.接触传播、呼吸道传播、血液传播", "E.呼吸道传播、母婴垂直传播、性传播"],
    "answer": "C"
  },
  {
    "id": 140,
    "question": "关于HIV的受体细胞的叙述,错误的是",
    "options": ["A.DC 细胞", "B.T细胞", "C.巨噬细胞", "D.B细胞", "E.CD4 T细胞"],
    "answer": "D"
  },
  {
    "id": 141,
    "question": "与垂直散射光(SSC)信号的强弱相关的是",
    "options": ["A.体积大小", "B.细胞形状", "C.细胞内颗粒的复杂度", "D.位移速度", "E.细胞膜分子表达水平"],
    "answer": "C"
  },
  {
    "id": 142,
    "question": "与前向散射光(FSC)信号成正比的是",
    "options": ["A.体积大小", "B.细胞性状", "C.颗粒多少", "D.位移速度", "E.荧光强弱"],
    "answer": "A"
  },
  {
    "id": 143,
    "question": "流式细胞术(flow cytometry)不用于",
    "options": ["A.T淋巴细胞及亚群分析", "B.淋巴细胞及亚群分析", "C.吞噬细胞分析", "D.白血病免疫分型", "E.细胞内细胞因子"],
    "answer": "C"
  },
  {
    "id": 144,
    "question": "散射光和激发荧光被光电倍增管接收的度数是",
    "options": ["A.90°", "B.60°", "C.30°", "D.45°", "E.80°"],
    "answer": "A"
  },
  {
    "id": 145,
    "question": "流式细胞分析技术中设置的同型对照是",
    "options": ["A.免疫荧光标记中的阳性对照", "B.免疫荧光标记中的阴性对照", "C.免疫荧光标记中的光校正", "D.免疫荧光标记中的流路校正", "E.免疫荧光标记中的绝对计数校正"],
    "answer": "B"
  },
  {
    "id": 146,
    "question": "对pH 工作环境变化最敏感的染料是",
    "options": ["A.得州红(Texas Red)", "B.FITC", "C.罗丹明 X", "D.藻红蛋白", "E.藻青蛋白"],
    "answer": "B"
  },
  {
    "id": 147,
    "question": "反射较长波长的光而通过较短波长的光的是",
    "options": ["A.气冷氩离子激光器", "B.分色反光镜", "C.光束成形器", "D.透镜组", "E.光电倍增管"],
    "answer": "B"
  },
  {
    "id": 148,
    "question": "关于单细胞悬液保存方法的叙述,错误的是",
    "options": ["A.深低温保存", "B.甲醇保存", "C.福尔马林保存", "D.多聚甲醛保存", "E.乙醇保存"],
    "answer": "C"
  },
  {
    "id": 149,
    "question": "线性放大器中输入信号放大10倍,输出信号放大",
    "options": ["A.1倍", "B.2倍", "C.3倍", "D.10倍", "E.100倍"],
    "answer": "D"
  },
  {
    "id": 150,
    "question": "固相膜免疫测定中常用的膜是",
    "options": ["A.玻璃纤维素膜", "B.尼龙膜", "C.聚偏氟乙烯膜", "D.硝酸纤维素膜", "E.聚苯乙烯膜"],
    "answer": "D"
  },
  {
    "id": 151,
    "question": "胶体金间接免疫层析法测血清抗体常设计成反流免疫层析法的主要目的是",
    "options": ["A.减少样品用量", "B.提高灵敏度", "C.提高特异性", "D.缩短反应时间", "E.减少血清标本中非特异免疫球蛋白对实验结果的干扰"],
    "answer": "E"
  },
  {
    "id": 152,
    "question": "关于金免疫层析试验竞争法结果判读的叙述,正确的是",
    "options": ["A.仅出现一条棕红色质控条带为阴性", "B.出现两条棕红色条带为阳性", "C.无棕红色质控条带出现为试剂失效", "D.都无棕红色条带出现即为阳性", "E.出现一条棕红色条带即为阳性"],
    "answer": "C"
  },
  {
    "id": 153,
    "question": "关于斑点金免疫渗滤试验双抗体夹心法的叙述,错误的是",
    "options": ["A.斑点颜色的深浅可提示阳性的强弱", "B.用胶体金标记抗原", "C.首先滴加纯化的抗体试剂", "D.膜中央出现红色斑点即为阳性反应", "E.以硝酸纤维素膜为载体"],
    "answer": "B"
  },
  {
    "id": 154,
    "question": "关于免疫印迹的叙述,错误的是",
    "options": ["A.也称酶联免疫电转移印迹法", "B.与Southern blot 相似也称为 Western blot", "C.试验第一阶段为SDS-PAGE 凝胶电泳", "D.试验第三阶段为电转移", "E.HIV 确证试验"],
    "answer": "D"
  },
  {
    "id": 155,
    "question": "关于固相膜的技术的叙述,错误的是",
    "options": ["A.孔径", "B.流速", "C.蛋白质结合力", "D.均一性", "E.膜厚度"],
    "answer": "E"
  },
  {
    "id": 156,
    "question": "在免疫金制备原理中,胶体金与蛋白质结合力为",
    "options": ["A.肽键结合力", "B.二硫键结合力", "C.氢键结合力", "D.静电引力", "E.疏水作用力"],
    "answer": "D"
  },
  {
    "id": 157,
    "question": "机体抗肿瘤效应最重要的细胞是",
    "options": ["A.巨噬细胞", "B.NK细胞", "C.B细胞", "D.CD4 Th细胞", "E.CD8+ Tc 细胞"],
    "answer": "E"
  },
  {
    "id": 158,
    "question": "与胰腺癌密切相关的标志物是",
    "options": ["A.CA19-9", "B.CA15-3", "C.CEA", "D.AFP", "E.CA125"],
    "answer": "A"
  },
  {
    "id": 159,
    "question": "关于病毒诱发肿瘤抗原特点的叙述,错误的是",
    "options": ["A.与病毒感染密切相关", "B.同一病毒诱导不同肿瘤并表达相同抗原", "C.具备明显个体差异性", "D.具有较强的免疫原性", "E.属于肿瘤相关抗原"],
    "answer": "C"
  },
  {
    "id": 160,
    "question": "属于肿瘤主动生物治疗方法的是",
    "options": ["A.LAK细胞治疗", "B.化疗", "C.TIL 治疗法", "D.接种肿瘤疫苗", "E.放射性核素标记 mAb"],
    "answer": "D"
  },
  {
    "id": 161,
    "question": "能诱发 Burkitt 淋巴瘤的病毒是",
    "options": ["A.乙型肝炎病毒", "B.EB病毒", "C.人乳头状瘤病毒", "D.巨细胞病毒", "E.单纯疱疹病毒"],
    "answer": "B"
  },
  {
    "id": 162,
    "question": "用于检测外周T细胞总数的CD分子是",
    "options": ["A.CD1", "B.CD2", "C.CD3", "D.CD4", "E.CD8"],
    "answer": "C"
  },
  {
    "id": 163,
    "question": "B细胞所特有的是",
    "options": ["A.Fc 受体", "B.补体受体", "C.SmIg", "D.EB病毒受体", "E.小鼠红细胞受体"],
    "answer": "C"
  },
  {
    "id": 164,
    "question": "检测细胞免疫缺陷的细胞免疫功能试验是",
    "options": ["A.溶血空斑试验", "B.免疫球蛋白检测", "C.淋巴细胞对PHA的免疫应答", "D.NBT还原试验", "E.速发性皮肤点刺试验"],
    "answer": "C"
  },
  {
    "id": 165,
    "question": "关于NK细胞活性检测方法的叙述,错误的是",
    "options": ["A.NK细胞介导的细胞毒作用", "B.形态学法", "C.化学发光法", "D.流式细胞术", "E.YAC-1作为靶细胞测定人NK细胞活性"],
    "answer": "E"
  },
  {
    "id": 166,
    "question": "关于转化的T淋巴细胞形态的叙述,错误的是",
    "options": ["A.细胞变大", "B.出现空泡", "C.核仁消失", "D.染色质疏松", "E.胞质扩大"],
    "answer": "C"
  },
  {
    "id": 167,
    "question": "关于免疫组织化学技术的叙述,错误的是",
    "options": ["A.ABC", "B.APAAP", "C.ELISA", "D.LSAB", "E.PAP"],
    "answer": "C"
  },
  {
    "id": 168,
    "question": "每个亲和素分子具有与生物素结合的位点的个数是",
    "options": ["A.1", "B.2", "C.3", "D.4", "E.5"],
    "answer": "D"
  },
  {
    "id": 169,
    "question": "过氧化物酶抗过氧化物酶法(PAP法)中的“桥”指的是",
    "options": ["A.第一抗体", "B.第二抗体", "C.第三抗体", "D.第四抗体", "E.亲和素"],
    "answer": "B"
  },
  {
    "id": 170,
    "question": "酶免疫组织化学染色技术中,酶底物颜色反应组合正确的是",
    "options": ["A.ALP-PNP呈橘红色", "B.HRP-DAB 呈棕色", "C.HRP-OPD 呈蓝色", "D.HRP-PNP 呈蓝色", "E.HRP-TMB呈黄色"],
    "answer": "B"
  },
  {
    "id": 171,
    "question": "补体结合法荧光抗体技术是将荧光素标记在",
    "options": ["A.补体", "B.抗补体抗体", "C.抗原", "D.第一抗体", "E.第二抗体"],
    "answer": "B"
  },
  {
    "id": 172,
    "question": "PAP 复合物中的酶是",
    "options": ["A.辣根过氧化物酶", "B.碱性磷酸酶", "C.葡萄糖氧化酶", "D.胃蛋白酶", "E.胶原酶"],
    "answer": "A"
  },
  {
    "id": 173,
    "question": "ABC法中的“桥”指的是",
    "options": ["A.第一抗体", "B.第二抗体", "C.第三抗体", "D.亲和素", "E.链霉素亲和素"],
    "answer": "D"
  },
  {
    "id": 174,
    "question": "荧光免疫组织化学技术中若标本固定干燥后置于4℃,最多可以保存",
    "options": ["A.数小时", "B.数天", "C.1个多月", "D.1年多", "E.永久"],
    "answer": "C"
  },
  {
    "id": 175,
    "question": "关于LSAB法(链霉亲和素生物素)的特点的叙述,错误的是",
    "options": ["A.敏感性高", "B.低背景着色", "C.一抗工作浓度低", "D.易于自动化", "E.操作简便"],
    "answer": "D"
  },
  {
    "id": 176,
    "question": "免疫组织化学技术吸收试验中过量的已知抗原与第一抗体充分反应的适宜温度为",
    "options": ["A.-20℃", "B.0~2℃", "C.2-8℃", "D.18-25℃", "E.37℃"],
    "answer": "C"
  },
  {
    "id": 177,
    "question": "关于组织细胞标本固定目的的叙述,错误的是",
    "options": ["A.防止细胞自溶", "B.使细胞内蛋白质凝固", "C.使细胞脱落", "D.保存组织细胞的抗原性", "E.保持细胞的形态与结构"],
    "answer": "C"
  },
  {
    "id": 178,
    "question": "关于抗原修复方法的叙述,错误的是",
    "options": ["A.微波法", "B.煮沸法", "C.冻融法", "D.酶消化法", "E.盐酸水解法"],
    "answer": "C"
  },
  {
    "id": 179,
    "question": "关于PAP法的叙述,错误的是",
    "options": ["A.PAP复合物结构稳定", "B.一抗和三抗的动物种属相同", "C.染色冲洗过程中酶分子不易脱落", "D.特异性高、重复性好", "E.敏感性比酶桥法低"],
    "answer": "E"
  },
  {
    "id": 180,
    "question": "关于免疫组织化学技术标本类型的叙述,错误的是",
    "options": ["A.粪便", "B.穿刺细胞", "C.培养细胞", "D.体腔渗出液", "E.手术切除组织"],
    "answer": "A"
  },
  {
    "id": 181,
    "question": "关于酶免疫组织化学技术的叙述,错误的是",
    "options": ["A.便于对组织细胞微细结构的分辨", "B.敏感性较荧光标记技术高", "C.可对组织、细胞抗原进行定性、定位、定量检测", "D.染色切片不能长期保存", "E.可用普通光镜观察结果"],
    "answer": "D"
  },
  {
    "id": 182,
    "question": "关于免疫组织化学切片制作过程中使用蛋白酶消化法的叙述,错误的是",
    "options": ["A.暴露组织抗原", "B.减少非特异性干扰", "C.限制抗原和抗体的结合", "D.利于抗原和抗体最大限度的结合", "E.增加细胞和组织的通透性"],
    "answer": "C"
  },
  {
    "id": 183,
    "question": "免疫学测定细胞因子的首选方法是",
    "options": ["A.化学发光免疫测定法", "B.间接免疫荧光法", "C.酶联免疫吸附法", "D.放射性核素检测法", "E.免疫比浊法"],
    "answer": "C"
  },
  {
    "id": 184,
    "question": "CD8 分子主要表达的细胞是",
    "options": ["A.Tc细胞", "B.Th细胞", "C.B细胞", "D.单核细胞", "E.巨噬细胞"],
    "answer": "A"
  },
  {
    "id": 185,
    "question": "关于细胞因子的叙述,错误的是",
    "options": ["A.生长因子(GF)", "B.干扰素(IFN)", "C.肿瘤坏死因子(TNF)", "D.集落刺激因子(CSF)", "E.植物血凝素(PHA)"],
    "answer": "E"
  },
  {
    "id": 186,
    "question": "对细胞免疫应答起负调节作用的是",
    "options": ["A.IL-1", "B.IL-2", "C.IL-3", "D.IL-4", "E.IL-8"],
    "answer": "D"
  },
  {
    "id": 187,
    "question": "类毒素刺激机体后产生的特异性免疫应答物质是",
    "options": ["A.干扰素", "B.抗毒素", "C.乙型溶素", "D.补体", "E.细胞因子"],
    "answer": "B"
  },
  {
    "id": 188,
    "question": "关于IL-2生物活性的叙述,错误的是",
    "options": ["A.刺激T细胞的生长", "B.促进T细胞和NK细胞产生细胞因子", "C.诱导T细胞发挥细胞毒作用", "D.抑制B细胞的生长及分化", "E.促进NK细胞的非特异性细胞杀伤作用"],
    "answer": "D"
  },
  {
    "id": 189,
    "question": "关于可溶性黏附分子的特性叙述,错误的是",
    "options": ["A.具有黏附分子的结合活性", "B.具有跨膜区和胞质区", "C.在调节细胞黏附途径中发挥重要作用", "D.可作为检测疾病病程和预后的指标", "E.参与免疫细胞的分化和发育"],
    "answer": "B"
  },
  {
    "id": 190,
    "question": "关于细胞增殖方式的叙述,错误的是",
    "options": ["A.H-TR掺入法", "B.MTT 比色法", "C.抗病毒活性法", "D.APT 法", "E.CAMP 法"],
    "answer": "C"
  },
  {
    "id": 191,
    "question": "关于细胞因子特点的叙述,错误的是",
    "options": ["A.分泌型蛋白质", "B.各有特异的生物学活性", "C.不受MHC 限制", "D.自分泌", "E.低分子量"],
    "answer": "B"
  },
  {
    "id": 192,
    "question": "关于细胞因子生物学检测方法的叙述,错误的是",
    "options": ["A.细胞增殖法", "B.靶细胞杀伤法", "C.重组细胞因子法", "D.细胞病变抑制法", "E.细胞因子诱导的产物分析法"],
    "answer": "C"
  },
  {
    "id": 193,
    "question": "关于免疫球蛋白与抗体关系的叙述,正确的是",
    "options": ["A.免疫球蛋白都具有抗体活性", "B.免疫球蛋白是抗体,但抗体不一定是免疫球蛋白", "C.抗体是免疫球蛋白,免疫球蛋白也就是抗体", "D.所有的抗体都是免疫球蛋白,但免疫球蛋白不一定都是抗体", "E.免疫球蛋白和抗体的结构完全不同"],
    "answer": "D"
  },
  {
    "id": 194,
    "question": "在局部黏膜免疫中发挥重要作用的免疫球蛋白是",
    "options": ["A.sIgA", "B.IgA", "C.IgE", "D.IgG", "E.IgM"],
    "answer": "A"
  },
  {
    "id": 195,
    "question": "某Rh(-)血型孕妇第一胎分娩Rh(+)胎儿,为了防止再次妊娠的Rh(+)胎儿产生新生儿溶血病,应给Rh母亲注射",
    "options": ["A.Rh抗原", "B.抗 Rh抗体", "C.免疫增强剂", "D.免疫抑制剂", "E.佛氏佐剂"],
    "answer": "B"
  },
  {
    "id": 196,
    "question": "血清中含量最高的免疫球蛋白是",
    "options": ["A.IgA", "B.IgD", "C.IgG", "D.IgE", "E.IgM"],
    "answer": "C"
  },
  {
    "id": 197,
    "question": "激活补体能力最强的免疫球蛋白是",
    "options": ["A.IgA", "B.IgD", "C.IgE", "D.IgG", "E.IgM"],
    "answer": "E"
  },
  {
    "id": 198,
    "question": "寄生虫感染时会明显水平升高的是",
    "options": ["A.IgA", "B.IgD", "C.IgE", "D.IgG", "E.IgM"],
    "answer": "C"
  },
  {
    "id": 199,
    "question": "与类风湿因子有关的是",
    "options": ["A.IgA", "B.IgD", "C.IgE", "D.IgG", "E.IgM"],
    "answer": "E"
  },
  {
    "id": 200,
    "question": "属于抗体的是",
    "options": ["A.溶血素", "B.植物血凝素", "C.过敏毒素", "D.细菌素", "E.抗生素"],
    "answer": "A"
  },
  {
    "id": 201,
    "question": "免疫调理作用最强的是",
    "options": ["A.IgA", "B.IgD", "C.IgE", "D.IgG", "E.IgM"],
    "answer": "E"
  },
  {
    "id": 202,
    "question": "关于各种免疫球蛋白单体分子共有特征的叙述,正确的是",
    "options": ["A.轻链与重链以非共价键结合", "B.与靶细胞结合后能介导 ADCC 作用", "C.具有两个完全相同的抗原结合部位", "D.与抗原结合后可以激活补体", "E.与颗粒性抗原结合后能介导调理吞噬作用"],
    "answer": "C"
  },
  {
    "id": 203,
    "question": "与补体旁路激活途径无关的是",
    "options": ["A.C2", "B.C3", "C.B因子", "D.D因子", "E.P因子"],
    "answer": "A"
  },
  {
    "id": 204,
    "question": "激活补体系统的三条途径的共同点是",
    "options": ["A.都形成相同的C3和C5转化酶", "B.参与的补体成分相同", "C.激活物质相同", "D.所需离子相同", "E.形成攻膜复合物"],
    "answer": "A"
  },
  {
    "id": 205,
    "question": "CP-CH50试验以红细胞溶解作为指示,一个CH50单位(U)是指",
    "options": ["A.引起10%溶血所需要的最小补体量", "B.引起25%溶血所需要的最小补体量", "C.引起50%溶血所需要的最小补体量", "D.引起75%溶血所需要的最小补体量", "E.引起100%溶血所需要的最小补体量"],
    "answer": "C"
  },
  {
    "id": 206,
    "question": "在AP-CH50试验中,缓冲液需加入EDTA以螯合的离子是",
    "options": ["A.Ca2+", "B.Fe", "C.Na", "D.Zn", "E.Mg"],
    "answer": "E"
  },
  {
    "id": 207,
    "question": "测定单个补体成分的溶血活性时,可以用酵母多糖灭活的补体成分是",
    "options": ["A.C1", "B.C2", "C.C3", "D.C4", "E.C5"],
    "answer": "C"
  },
  {
    "id": 208,
    "question": "补体结合试验前需对血清标本做56℃ 30min处理,其目的是",
    "options": ["A.有利于抗原抗体反应", "B.增加补体活性", "C.有利于补体系统激活", "D.灭活补体并去除非特异性反应因素", "E.有利于致敏SRBC 激活"],
    "answer": "D"
  },
  {
    "id": 209,
    "question": "关于CP-CH50试验的方法学的叙述,错误的是",
    "options": ["A.提供越高浓度的 Ca2+ 和 Mg2+ 越能促进溶血反应", "B.过量的 Ca2+ 和 Mg2+ 会抑制溶血反应", "C.缓冲液的离子强度和pH影响补体活性", "D.溶血程度与补体活性在一定范围内呈正相关", "E.该方法简便、快速,敏感性低"],
    "answer": "A"
  },
  {
    "id": 210,
    "question": "补体水平一般不发生下降的情况是",
    "options": ["A.肾病综合征", "B.大面积烧伤", "C.肝硬化", "D.妊娠", "E.系统性红斑狼疮"],
    "answer": "D"
  },
  {
    "id": 211,
    "question": "临床进行器官移植最常见的类型是",
    "options": ["A.自体移植", "B.同系移植", "C.同种异体移植", "D.异种移植", "E.细胞移植"],
    "answer": "C"
  },
  {
    "id": 212,
    "question": "HLA 各位点在器官移植配型时抗原匹配程度最重要的是",
    "options": ["A.HLA-A", "B.HLA-B", "C.HLA-C", "D.HLA-DR", "E.HLA-DQ"],
    "answer": "D"
  },
  {
    "id": 213,
    "question": "关于同种异体抗原直接识别与间接识别的区别的叙述,错误的是",
    "options": ["A.供者 APC 还是受者 APC", "B.对免疫抑制剂的敏感程度", "C.发生的时相不同", "D.供受者的HLA差异程度不同", "E.产生的T细胞克隆所占比重不同"],
    "answer": "D"
  },
  {
    "id": 214,
    "question": "实体器官移植时,HLA交叉配型的目的是",
    "options": ["A.检测受者血清中是否有针对供者的抗体", "B.检测受者淋巴细胞表面的HLA抗原", "C.检测供者血清中是否有针对受者的抗体", "D.检测供者淋巴细胞表面的HLA抗原", "E.检测供者和受者的ABO血型抗原"],
    "answer": "A"
  },
  {
    "id": 215,
    "question": "移植物抗宿主反应主要发生于",
    "options": ["A.肝移植", "B.心脏移植", "C.肺移植", "D.外周血干细胞移植", "E.肾移植"],
    "answer": "D"
  },
  {
    "id": 216,
    "question": "宿主抗移植物反应最常见的类型是",
    "options": ["A.慢性排斥反应", "B.亚急性排斥反应", "C.急性排斥反应", "D.超急性排斥反应", "E.远期排斥反应"],
    "answer": "A"
  },
  {
    "id": 217,
    "question": "发生急性排斥反应时,正确的是",
    "options": ["A.CD4/CD8值下降", "B.CD4/CD8值升高", "C.IL-2水平下降", "D.IL-2受体水平下降", "E.IL-1水平下降"],
    "answer": "B"
  },
  {
    "id": 218,
    "question": "常用于检测淋巴细胞HLA抗原的血清学试验是",
    "options": ["A.混合淋巴细胞细胞培养", "B.补体结合试验", "C.血凝试验", "D.补体依赖的细胞毒试验", "E.单向扩散试验"],
    "answer": "D"
  },
  {
    "id": 219,
    "question": "移植患者使用免疫抑制剂治疗的常见不良反应是",
    "options": ["A.自身免疫病", "B.超敏反应", "C.原发性免疫缺陷", "D.重度营养不良", "E.感染和肿瘤"],
    "answer": "E"
  },
  {
    "id": 220,
    "question": "预防骨髓移植术后发生移植物抗宿主反应的有效措施是",
    "options": ["A.术前清髓", "B.HLA 配型", "C.ABO血型配型", "D.诱导特异性免疫耐受", "E.进行免疫抑制"],
    "answer": "D"
  },
  {
    "id": 221,
    "question": "宫颈与阴道上皮的T细胞主要是",
    "options": ["A.CD2+T细胞", "B.CD3+T细胞", "C.CD4+T细胞", "D.CD8+T细胞", "E.CD45+T细胞"],
    "answer": "D"
  },
  {
    "id": 222,
    "question": "在母体-胎盘免疫免疫耐受中起主要作用的是",
    "options": ["A.HLA-A", "B.HLA-B", "C.HLA-C", "D.HLA-D", "E.HLA-G"],
    "answer": "E"
  },
  {
    "id": 223,
    "question": "能通过胎盘屏障导致胎儿溶血性贫血的抗体类型是",
    "options": ["A.IgA", "B.IgD", "C.IgE", "D.IgG", "E.IgM"],
    "answer": "D"
  },
  {
    "id": 224,
    "question": "关于妊娠妇女血清中存在封闭性抗体的叙述,错误的是",
    "options": ["A.抗HLA-DR抗体", "B.抗透明带抗体", "C.抗Fc受体抗体", "D.抗 TLX 抗体", "E.抗冷B细胞抗体"],
    "answer": "B"
  },
  {
    "id": 225,
    "question": "抗磷脂抗体可引起反复自然流产,用ELISA法检测时包被抗原可采用",
    "options": ["A.牛心磷脂", "B.人心磷脂", "C.猪心磷脂", "D.人工合成磷脂", "E.类脂质"],
    "answer": "A"
  },
  {
    "id": 226,
    "question": "属于同种免疫产生的抗体是",
    "options": ["A.抗子宫内膜抗体", "B.抗滋养层细胞抗体", "C.封闭抗体", "D.抗卵巢抗体", "E.抗心磷脂抗体"],
    "answer": "C"
  },
  {
    "id": 227,
    "question": "关于抗精子抗体检测的叙述,错误的是",
    "options": ["A.精子凝集试验用于分析女方血清,特异性差", "B.精子制动试验特异性强、敏感性差、假阴性率低", "C.ELISA法检测显色深浅与抗精子抗体的量成正比", "D.免疫微球结合法不能进行定量测定", "E.通常检测血清中的IgG型抗体"],
    "answer": "B"
  },
  {
    "id": 228,
    "question": "活化生物素标记大分子蛋白质后,影响生物素活性的主要因素是",
    "options": ["A.大分子蛋白质中的赖氨酸的氨基", "B.连接臂的6-氨基己糖基团", "C.大分子蛋白质的空间位阻效应", "D.大分子蛋白质的等电点发生改变", "E.大分子蛋白质的肽链断裂"],
    "answer": "C"
  },
  {
    "id": 229,
    "question": "生物素分子中,与亲和素结合的主要部位是",
    "options": ["A.噻吩环", "B.咪唑酮环", "C.苯环", "D.-NH-", "E.羰基"],
    "answer": "B"
  },
  {
    "id": 230,
    "question": "生物素亲和素系统放大作用的机制主要是",
    "options": ["A.生物素、亲和素之间为特异性结合", "B.生物素、亲和素可与酶、荧光素等结合形成标志物", "C.生物素、亲和素之间具有极高的亲和力", "D.经化学修饰后,生物素成为活化生物素", "E.亲和素的4个相同亚基可同时结合生物素化衍生物"],
    "answer": "E"
  },
  {
    "id": 231,
    "question": "在亲和素-生物素系统中,亲和素和生物素的比例是",
    "options": ["A.1:1", "B.2:1", "C.1:4", "D.1:2", "E.4:1"],
    "answer": "C"
  },
  {
    "id": 232,
    "question": "亲和素-生物素化酶复合物被简称为",
    "options": ["A.PAP", "B.ACB", "C.BAB", "D.ABC", "E.CAB"],
    "answer": "D"
  },
  {
    "id": 233,
    "question": "关于亲和素特点的叙述,错误的是",
    "options": ["A.含糖约10%", "B.耐热", "C.与生物素结合,其稳定性变差", "D.与生物素结合不受pH影响", "E.与生物素结合,不受蛋白质变性剂影响", "F.耐受多种蛋白质水解酶"],
    "answer": "C"
  },
  {
    "id": 234,
    "question": "生物素-亲和素系统不常用于",
    "options": ["A.微生物鉴定和分型", "B.微量抗原定性", "C.微量抗体定性", "D.抗原抗体定量", "E.抗原抗体反应的定位", "F.提高酶联免疫反应的敏感性"],
    "answer": "A"
  },
  {
    "id": 235,
    "question": "关于生物素-亲和素-酶复合物特点的叙述,错误的是",
    "options": ["A.利用亲和素连接生物素标记的第二抗体", "B.利用亲和素连接生物素标记的酶", "C.复合物中的酶分子与多个生物素连接", "D.一个亲和素分子可桥联多个酶标生物素分子", "E.ABC的弱点是其背景信号强于LAB法和BAB法"],
    "answer": "E"
  },
  {
    "id": 236,
    "question": "关于链霉亲和素的叙述,错误的是",
    "options": ["A.是链霉菌培养过程中分泌的蛋白质", "B.分子质量约为65kDa", "C.由4条序列相同的肽段组成", "D.为弱碱性蛋白", "E.等电点为6.0左右"],
    "answer": "D"
  },
  {
    "id": 237,
    "question": "关于亲和素-生物素系统的叙述,错误的是",
    "options": ["A.用于间接包被", "B.用于终反应放大", "C.用于酶免疫测定", "D.用于胶体金测定", "E.增加抗原抗体反应的稳定性"],
    "answer": "E"
  },
  {
    "id": 238,
    "question": "ABC-ELISA将酶标记于",
    "options": ["A.亲和素", "B.生物素", "C.抗体", "D.补体", "E.抗原"],
    "answer": "B"
  },
  {
    "id": 239,
    "question": "BAS 在ELISA 技术中应用最广泛的反应模式是",
    "options": ["A.BAB", "B.ABC", "C.BRAB", "D.BA", "E.LAB"],
    "answer": "B"
  },
  {
    "id": 240,
    "question": "在一组免疫学检测中,所有测定值处于均值±2s范围内的概率为",
    "options": ["A.0.68", "B.0.90", "C.0.95", "D.0.99", "E.0.997"],
    "answer": "C"
  },
  {
    "id": 241,
    "question": "进行免疫学实验室室间质评的目的是",
    "options": ["A.评估免疫学实验室整体检测能力", "B.评估免疫学实验室工作人员的个人检测能力", "C.评估样本免疫学检测的重复性", "D.计算样本免疫学检测的平均值、CV值和标准差", "E.样本免疫学检测的方法学评估"],
    "answer": "A"
  },
  {
    "id": 242,
    "question": "Levey-Jennings 质控图以±3S作为",
    "options": ["A.警告限", "B.失控限", "C.在控限", "D.误差限", "E.显著限"],
    "answer": "B"
  },
  {
    "id": 243,
    "question": "关于定量免疫学检验的质控物要求的叙述,错误的是",
    "options": ["A.浓度在测定范围以内", "B.应有低浓度质控品", "C.测定方法检出下限浓度的质控品", "D.中浓度质控品", "E.高浓度质控品"],
    "answer": "C"
  },
  {
    "id": 244,
    "question": "免疫测定中质控品要求的前提是基质应为",
    "options": ["A.小牛血清", "B.兔血清", "C.人血清", "D.马血清", "E.哺乳动物血清"],
    "answer": "C"
  },
  {
    "id": 245,
    "question": "免疫学检测中,偏倚是指",
    "options": ["A.待测物测定值与真值的一致性程度", "B.独立测定结果之间的一致性程度", "C.待测物测定值与可接受参考值之间的差异", "D.短时间内获得的独立结果的一致性程度", "E.测定数据的离散程度"],
    "answer": "A"
  },
  {
    "id": 246,
    "question": "通常用ELISA方法检测时,测定的OCV应",
    "options": ["A.<5%", "B.<10%", "C.>10%", "D.<15%", "E.>15%"],
    "answer": "D"
  },
  {
    "id": 247,
    "question": "定性免疫检测方法在进行室内质控时,每次测定都应带",
    "options": ["A.阳性对照", "B.阴性对照", "C.阳性、阴性对照", "D.弱阳性对照", "E.强阳性对照"],
    "answer": "D"
  },
  {
    "id": 248,
    "question": "1924年,首先提出质控图的现代质量管理的奠基者是",
    "options": ["A.Whitehead", "B.Levey", "C.Shewhart", "D.Jinnings", "E.Westgard"],
    "answer": "C"
  },
  {
    "id": 249,
    "question": "定量免疫检测时,除对仪器进行校准外,应选择的质控品是",
    "options": ["A.高、中、低三种浓度", "B.高浓度", "C.中浓度", "D.低浓度", "E.中、低浓度"],
    "answer": "A"
  },
  {
    "id": 250,
    "question": "通常使用自动化免疫分析仪进行检测时,其测定的OCV应",
    "options": ["A.<5%", "B.<15%", "C.>15%", "D.<10%", "E.>10%"],
    "answer": "D"
  },
  {
    "id": 251,
    "question": "在免疫学检测中,将标准差以其均值的百分比来表示的是",
    "options": ["A.重复性条件", "B.批内精密度", "C.变异系数", "D.均值", "E.标准差"],
    "answer": "C"
  }
]